肿瘤细胞治疗研究
FRONTIER PAPERS
One-step knock-in CAR constructs in human NK cells enable scalable, TGFβ1-resistant immunotherapy for solid tumors.
我们采用无病毒、一步工程化策略，设计了稳健的、抗 TGF 1 的同种异体 CAR-NK 细胞，建立了一种通用且临床可规模化的方法，用于工程化改造代谢增强的 CAR-NK 细胞，使其能够克服实体瘤中 TME 介导的免疫抑制。
Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma.
本研究提出了一种协同免疫治疗平台，整合了 NK 重编程、CAR 工程和肿瘤增敏。该联合方案显著增强了 PDAC 中的抗肿瘤疗效，并为克服实体瘤中的免疫抵抗提供了一种有前景的策略。
Supercharging the metabolic engine: mitochondrial engineering strategies for CAR-T persistence in solid tumors.
A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.
这些发现表明，表面 MUC21 是一种强效免疫抑制配体，可保护癌细胞免受 NK 和 CD8⁺ T 细胞的攻击。
Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells.
Enhancing cancer killing and natural killer cell persistence by targeting NOXA, a predictor of poor patient survival.
Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine.
Monovalent Anti-CD3 Antibodies Effectively Eliminate the TCR-Positive Fraction of TCR-Deleted Allogeneic CAR-T Cells to Prevent GVHD.
Genetically stable multi-gene edited iPSCs-derived NK cells for enhanced cancer immunotherapy.
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
